Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
about
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Moving forward with treatment options for HIV-infected children.Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.The pharmacological treatment of acute HIV infections in neonates.
P2860
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@ast
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@en
type
label
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@ast
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@en
prefLabel
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@ast
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@en
P2093
P2860
P356
P1476
Pharmacokinetics and 48-Week S ...... dren 4 Weeks to 2 Years of Age
@en
P2093
Andrew Wiznia
Bobbie Graham
Brenda Homony
Carmelita Alvero
Carol Worrell
Edward Handelsman
Edward P Acosta
Hedy Teppler
Lisa M Frenkel
Matthew L Rizk
P2860
P304
P356
10.1093/JPIDS/PIU146
P577
2015-02-07T00:00:00Z